单核细胞趋化蛋白-1、白细胞介素-6和一氧化氮与脑小血管病患者认知功能的相关性

doi:10.20047/j.issn1673-7210.2023.14.18

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (712 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨单核细胞趋化蛋白-1（MCP-1）、白细胞介素-6（IL-6）和一氧化氮（NO）与脑小血管病（CSVD）患者认知功能的相关性。方法收集2020年9月至2021年9月河北北方学院附属第一医院（以下简称“我院”）神经内三科确诊CSVD且蒙特利尔认知评估（MoCA）评分＜26分的患者130例作为观察组，并收集同期我院脑部影像学无异常且MoCA评分≥26分的患者80例作为对照组。对两组血清MCP-1、IL-6、NO进行比较，分析CSVD认知功能障碍的影响因素，采用受试者操作特征曲线分析诊断价值，并进一步分析MCP-1、IL-6、NO与患者MoCA评分的相关性。结果观察组血清MCP-1、IL-6高于对照组，血清NO、MoCA评分低于对照组，差异有统计学意义（P＜0.05）。多因素分析结果显示，血清MCP-1（OR=1.055，95%CI：1.037～1.074）、IL-6（OR=1.659，95%CI：1.431～1.923）、NO（OR=0.836，95%CI：0.785～0.891）水平是发生CSVD认知功能障碍的独立影响因素。受试者操作特征曲线分析结果显示，血清MCP-1、IL-6、NO联合预测CSVD认知功能障碍的曲线下面积为0.880（P＜0.05），灵敏度为82.3%，特异度为83.8%。血清NO水平与CSVD认知功能障碍患者MoCA评分呈正相关（r＞0，P＜0.05），血清MCP-1、IL-6水平与其呈负相关（r＜0，P＜0.05）。结论 CSVD认知功能障碍患者血清MCP-1、IL-6水平升高，NO水平降低，并与其认知功能水平相关，联合检测三项指标有助于预测CSVD认知功能障碍的发生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘传芬1　　宋征宇2　　张晓丽2　　胡瑾2▲

关键词 ：脑小血管病, 认知功能, 单核细胞趋化因子-1, 白细胞介素-6, 一氧化氮

Abstract：Objective To investigate the association between monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), nitric oxide (NO), and cognitive function in patients with cerebrovascular disease (CSVD). Methods A total of 130 patients diagnosed with CSVD in the First Affiliated Hospital of Hebei North University (hereinafter referred to as “our hospital”) from September 2020 to September 2021 with Montreal cognitive assessment (MoCA) score ＜26 points were collected as the observation group. In addition, 80 patients with no abnormal brain imaging and MoCA score ≥26 points in our hospital during the same period were collected as the control group. Serum MCP-1, IL-6, and NO were compared between the two groups, and the influencing factors of CSVD cognitive dysfunction were analyzed. The diagnostic value was analyzed by the receiver operator characteristic curve, and the correlation between MCP-1, IL-6, NO, and the MoCA score of patients was further analyzed. Results The levels of serum MCP-1 and IL-6 in the observation group were higher than those in the control group, and the serum NO and MoCA scores were lower than those in the control group, the differences were statistically significant (P＜0.05). Multivariate analysis showed that serum MCP-1 (OR=1.055, 95%CI: 1.037-1.074), IL-6 (OR=1.659, 95%CI: 1.431-1.923), NO(OR=0.836, 95%CI: 0.785-0.891) level was independent factors of CSVD cognitive dysfunction. The results of receiver operator characteristic curve analysis showed that the area under the curve of serum MCP-1, IL-6, and NO combined to predict CSVD cognitive dysfunction was 0.880 (P＜0.05), the sensitivity was 82.3%, and the specificity was 83.8%. Serum NO level was positively correlated with MoCA scores in patients with CSVD cognitive dysfunction (r＞0, P＜0.05), while serum MCP-1 and IL-6 levels were negatively correlated with it (r＜0, P＜0.05). Conclusion In patients with CSVD cognitive dysfunction, the levels of serum MCP-1 and IL-6 are increased, while the level of NO is decreased, which are correlated with the level of cognitive function. The combined detection of the three indicators is helpful to predict the occurrence of CSVD cognitive dysfunction.

Key words： Cerebral small vessel disease Cognitive function Monocyte chemokine-1 Interleukin-6 Nitric oxide

基金资助:河北省中医药管理局中医药类科学研究课题计划项目（2023100）。

通讯作者: ▲通讯作者

作者简介: 刘传芬（1993.5-），女，河北北方学院2020级神经病学专业在读硕士研究生；研究方向：神经病学。

引用本文:

刘传芬1　　宋征宇2　　张晓丽2　　胡瑾2▲. 单核细胞趋化蛋白-1、白细胞介素-6和一氧化氮与脑小血管病患者认知功能的相关性[J]. 中国医药导报, 2023, 20(14): 86-89,110.
LIU Chuanfen1　SONG Zhengyu2　ZHANG Xiaoli2　HU Jin2▲. Association of monocyte chemotactic protein-1, interleukin-6, and nitric oxide with cognitive function in patients with cerebrovascular disease. 中国医药导报, 2023, 20(14): 86-89,110.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.14.18 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I14/86

[1] 乔杉杉，张拥波，赵莹莹，等.脑小血管病临床生化标志物研究进展[J]临床和实验医学杂志，2020，19（6）：671-673.
[2] 李譞婷，胡文立.脑小血管病影像学标志物之间关联性研究的进展[J]中华脑血管病杂志（电子版）2021，15（4）：218-221.
[3] Chojdak-?覵ukasiewicz J，Dziadkowiak E，Zimny A，et al. Cerebral small vessel disease：A review [J]. Adv Clin Exp Med，2021，30（3）：349-356.
[4] 杜昕姝，李国忠.脑小血管病治疗与预后[J]中国实用内科杂志，2021，41（7）：571-574.
[5] Ren B，Tan L，Song Y，et al. Cerebral Small Vessel Disease：Neuroimaging Features，Biochemical Markers，Influencing Factors，Pathological Mechanism and Treatment [J]. Front Neurol，2022，13：843953.
[6] Kalaria RN，Sepulveda-Falla D. Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease [J]. Am J Pathol，2021，191（11）：1888-1905.
[7] Zanon Zotin MC，Sveikata L，Viswanathan A，et al. Cerebral small vessel disease and vascular cognitive impairment：from diagnosis to management [J]. Curr Opin Neurol，2021，34（2）：246-257.
[8] Guy R，Volkman R，Wilczynski E，et al. A Novel Rodent Model of Hypertensive Cerebral Small Vessel Disease with White Matter Hyperintensities and Peripheral Oxidative Stress [J]. Int J Mol Sci，2022，23（11）：5915-5931.
[9] Evans LE，Taylor JL，Smith CJ，et al. Cardiovascular comorbidities，inflammation，and cerebral small vessel disease [J]. Cardiovasc Res，2021，117（13）：2575-2588.
[10] Quick S，Moss J，Rajani RM，et al. A Vessel for Change：Endothelial Dysfunction in Cerebral Small Vessel Disease [J]. Trends Neurosci，2021，44（4）：289-305.
[11] Singh S，Anshita D，Ravichandiran V. MCP-1：Function，regulation，and involvement in disease [J]. Int Immunopharmacol，2021，101（Pt B）：107598.
[12] Kang S，Narazaki M，Metwally H，et al. Historical overview of the interleukin-6 family cytokine [J]. Exp Med，2020， 217（5）：e20190347.
[13] Liao FF，Lin G，Chen X，et al. Endothelial Nitric Oxide Synthase-Deficient Mice：A Model of Spontaneous Cerebral Small-Vessel Disease [J]. Am Pathol，2021，191（11）：1932- 1945.
[14] Kang JM，Cho YS，Park S，et al. Montreal cognitive assessment reflects cognitive reserve [J]. BMC Geriatr，2018，18（1）：261.
[15] 胡文立，杨磊，李譞婷，等.中国脑小血管病诊治专家共识2021[J].中国卒中杂志， 2021，16（7）：716-726.
[16] Lyra E，Silva NM，Gon?觭alves RA，et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease [J]. Transl Psychiatry，2021，11（1）：251.
[17] Murakami M，Kamimura D，Hirano T. Pleiotropy and Specificity：Insights from the Interleukin 6 Family of Cytokines [J]. Immunity，2019，50（4）：812-831.
[18] Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1：Moving Upstream To Identify Novel Targets for Atheroprotection [J]. Circ Res，2016，118（1）：145-156.
[19] Lin J，Li G，Xu C，et al. Monocyte Chemotactic Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities [J]. Mediators Inflamm，2020，2020：8812020.
[20] Yang C，Hawkins KE，Dore S，et al. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke [J]. Am J Physiol Cell Physiol，2019，316（2）：C135- C153.
[21] Tsui A，Davis D. Systemic inflammation and causal risk for Alzheimer’s dementia：Possibilities and limitations of a Mendelian randomization approach [J]. Aging Med（Milton），2018，1（3）：249-253.
[22] Xu Y，Shen YY，Zhang XP，et al. Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer’s disease and amnestic mild cognitive impairment [J]. Eur J Neurol，2020，27（8）：1429-1435.
[23] Porcellini E，Ianni M，Carbone I，et al. Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimer’s disease [J]. Immun Ageing，2013，10（1）：6.
[24] Tewari D，Sah AN，Bawari S，et al. Role of Nitric Oxide in Neurodegeneration：Function，Regulation，and Inhibition [J]. Curr Neuropharmacol，2021，19（2）：114-126.
[25] Luczak A，Madej M，Kasprzyk A，et al. Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases [J]. Oxid Med Cell Longev，2020，2020：1417981.
[26] Prado AF，Batista RIM，Tanus-Santos JE，et al. Matrix Metalloproteinases and Arterial Hypertension：Role of Oxidative Stress and Nitric Oxide in Vascular Functional and Structural Alterations [J]. Biomolecules，2021，11（4）：585.